FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment

The FDA has granted approval for a subcutaneous starting dose regimen of lecanemab, known as Leqembi. This regulatory decision allows individuals with early-stage Alzheimer disease to initiate treatment at home through weekly self-injections. Previously, patients were required to undergo 18 months of intravenous infusions before becoming eligible for at-home subcutaneous administration.

This change removes a significant barrier to care. Infusion center visits often create logistical and financial burdens for patients and their caregivers. By allowing patients to start treatment from home, the new protocol provides a more direct path for those managing the early stages of the disease. The subcutaneous formulation is supported by data demonstrating bioequivalence to the intravenous version, as well as evidence of effective amyloid plaque clearance.

Clinical experts note that this shift serves as an inflection point for the treatment of Alzheimer disease. As delivery methods become more practical, the medical community can move closer to long-term combination therapies. Similar to how cancer care shifted toward outpatient models, this development allows for more flexible and sustainable treatment plans.

While this approval increases accessibility, the safety profile remains consistent with previous findings. Patients and providers must continue to monitor for amyloid-related imaging abnormalities. Screening for ApoE e4 status is recommended, and caution is advised for patients taking anticoagulants. Despite these clinical requirements, the ability to manage the induction phase at home is expected to generate billions in societal savings by reducing the costs associated with infusion services and time expenditures.